K
Kymera Therapeutics, Inc. (KYMR)
NGM – Real vaqt narxi. Valyuta: USD
83.55
-0.55 (-0.65%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
83.55
-0.55 (-0.65%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Kymera Therapeutics, Inc. klinik bosqichdagi biofarmatsevtika kompaniyasi bo'lib, organizmning o'zining tabiiy oqsil parchalanish tizimidan foydalangan holda, kasallikni keltirib chiqaruvchi oqsillarni tanlab yo'q qiladigan kichik molekulali dorilarni kashf qilish va ishlab chiqishga qaratilgan. Kompaniya mo''tadil va og'ir atopik dermatit, astma, O'PKD, EoE, CRSwNP, CSU, PN, BP va boshqa kasalliklar uchun 2b bosqichli klinik sinovlarda bo'lgan og'iz orqali qabul qilinadigan STAT6 parchalovchisi KT-621; tizimli qizil yug'rich, revmatoid artrit, yallig'lanish ichak kasalliklari, SSc, DM va boshqalar kabi otoimmün kasalliklar uchun 1-bosqichli klinik sinovlarda bo'lgan og'iz orqali qabul qilinadigan IRF5 parchalovchisi KT-579; gidradenit suppurativ va atopik dermatitni o'z ichiga olgan immun-yallig'lanish kasalliklarini davolash uchun II bosqichli klinik sinovda bo'lgan IRAK4 dasturi KT-485/SAR447971; va ko'krak bezi saratoni va boshqa qattiq o'smalarni o'z ichiga olgan keng onkologik davolash potentsialiga ega siklin-bog'liq kinaza 2 (CDK2) ni ishlab chiqish bilan shug'ullanadi. Kompaniya onkologiya va immuno-onkologiya sohalaridan tashqari IRAK4 ga qarshi dorilarni ishlab chiqish uchun Sanofi S.A. bilan strategik ittifoqqa ega. Kymera Therapeutics, Inc. 2015 yilda tashkil etilgan va shtab-kvartirasi Massachusets shtatining Uoterdaun shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Bruce L. Booth DPHIL, Ph.D. | Co-Founder & Independent Chairman |
| Dr. Jared A. Gollob M.D. | Chief Medical Officer |
| Dr. Jeremy G. Chadwick Ph.D. | Chief Operating Officer |
| Dr. Neil Graham M.D., M.P.H., MBBS | Chief Development Officer |
| Dr. Nello Mainolfi M.D., Ph.D. | Co-Founder, President, CEO & Director |
| Mr. Brian R. Adams J.D. | Chief Legal Officer & Corporate Secretary |
| Mr. Bruce N. Jacobs CFA | Chief Financial Officer |
| Mr. Noah Goodman M.B.A. | Chief Business Officer |
| Ms. Justine E. Koenigsberg | Vice President of Investor Relations |
| Ms. Karen Weisbach | Head of People & Culture |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | 8-K | kymr-20260430.htm |
| 2026-04-30 | 10-Q | kymr-20260331.htm |
| 2026-04-29 | DEFA14A | kymr_defa14a_2025.htm |
| 2026-03-27 | 8-K | d122194d8k.htm |
| 2026-02-26 | 10-K | kymr-20251231.htm |
| 2026-01-13 | 8-K | d78447d8k.htm |
| 2025-12-10 | 8-K | d89982d8k.htm |
| 2025-11-04 | 10-Q | kymr-20250930.htm |
| 2025-09-03 | 8-K | d94060d8k.htm |
| 2025-08-11 | 8-K | kymr-20250811.htm |